Luis F. López-Cortes

Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection

E. Poveda, A. Fernández-Villar, M. Bernabeu-Wittel, 2021, Cellular & Molecular Immunology.

DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

J. Pasquau, Sergio Ferra-Murcia, C. García-Vallecillos, 2024, Viruses.

Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life

A. Gutiérrez-Valencia, Silvia Llaves-Flores, Nuria Espinosa, 2024, Microbiology spectrum.

Stepped-Dose vs . Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events A Randomized Trial

A. Terrón, R. Ruiz-Valderas, A. Gutiérrez-Valencia, 2009 .

The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers

E. Ruiz-Mateos, M. Perreau, J. Peraire, 2024, The Journal of clinical investigation.

HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors.

E. Ruiz-Mateos, A. Gutiérrez-Valencia, Esperanza Muñoz-Muela, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors

C. Lozano, A. Gutiérrez-Valencia, Esperanza Muñoz-Muela, 2024, Frontiers in immunology.

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

E. Ruiz-Mateos, B. Mothe, A. Pérez-Gómez, 2024, JCI insight.